Disease Diagnosis TRIZ Cases

GFAP-specific IgG autoantibodies identify autoimmune astrocytopathy, enabling early cancer detection and targeted immunotherapy.

Repeated incubation and mechanical disruption cycles amplify trace misfolded proteins to enable sensitive fluorescence detection for early disease diagnosis.

Segmenting NGAL into molecular forms resolves diagnostic ambiguity between renal injury and systemic inflammation.

Monoclonal antibodies detect CAPRIN-1 expression levels in patient samples to enable targeted therapeutic drug selection.

A multiplexed assay kit measures specific autoantibodies including MVP and RPS13 to evaluate systemic lupus erythematosus presence.

FLC biomarker panels resolve the trade-off between general diagnostic capability and specificity for viral infection complications in heart disease.

Detecting total free light chains in blood samples identifies elevated biomarker levels associated with diabetic complications.

Exercise amplifies biomarker signals for rapid evaluation, resolving the trade-off between diagnostic accuracy and study duration.

Measuring lipoprotein sterol uptake per unit volume identifies diabetes onset risk through a non-invasive optical detection method.

Measuring nematode attraction changes in urine overcomes biomarker sensitivity limits, enabling precise recurrence monitoring.

BIN1 protein levels in bodily fluids assess cardiac health status and predict mortality risk.

Capillary electrophoresis detects serum N-glycans to predict hepatocellular carcinoma recurrence, overcoming limited sensitivity of current imaging criteria.

Proximity assay measures phospho-PI3K and phospho-AKT levels to predict patient responsiveness to PI3K inhibitors.

A test strip system detects tear protein concentrations via immuno-chemical reactions.

Azacitidine restores DPH1 expression to reverse resistance and improve treatment efficacy.

MALDI-TOF MS detects glycated hemoglobin to enable affordable pre-diabetes diagnosis without variant hemoglobin interference.

Segmenting CA125 measurement via immune cell binding resolves false positives from pregnancy and endometriosis while improving diagnostic reliability.

A phagocytic shuttle method isolates neural debris from circulating blood cells to enable non-invasive monitoring of brain health.

Segmenting multiple inflammatory markers improves diagnostic accuracy while reducing hospital mortality in fulminant myocarditis patients.

Measuring FOS and DUSP1 gene expression in peripheral blood monocytes replaces invasive surgical procedures with a reliable molecular diagnostic approach.

Measuring anti-GM-CSF antibodies resolves diagnostic accuracy limits by enabling precise treatment selection and timely intervention.

A biomarker panel detects hepatocellular carcinoma through laminin gamma 2 monomer and PIVKA-II analysis.

A recombinant deamidated gliadin antigen hexamer reduces false positives and negatives by providing a comprehensive epitope set for accurate celiac diagnosis.

Cultured fibroblasts exhibit distinct aggregate and migration patterns that differentiate Alzheimer's disease from healthy cells.

A monoclonal antibody specifically reacts with high-molecular weight adiponectin to enable selective measurement.

Soluble VSIG4 biomarkers resolve sepsis diagnostic reliability issues by distinguishing infectious from non-infectious inflammation with high sensitivity.

Assays biological fluids for specific protein markers to predict labor onset accurately.

Human monoclonal antibodies selectively bind prostasomes to resolve diagnostic accuracy versus specificity contradictions in prostate cancer screening.

Antibodies bind BCL2 and BIM heterodimers to detect tumor samples directly.

Nanobeads coated with plasminogen capture pathogenic prion proteins directly on a solid support.

Short-interval IL-6 monitoring detects systemic inflammatory response syndrome before clinical signs appear.

Detecting glycosylated Apo J via lectin binding resolves delayed troponin diagnosis by identifying early ischemic changes before irreversible necrosis occurs.

A biomarker panel measures IFNλ3, CCL17, CXCL11, IP-10, IL-6, and CXCL9 concentrations to predict respiratory infection status.

IFNγ+IL-10+IL-34 secreting CD8+CD45RClow T regulatory cells provide targeted immune modulation.

A sensor array of conductive nanoparticles analyzes exhaled breath VOCs to differentiate benign from malignant tumors without radiation exposure.

A lateral flow device detects visinin-like proteins in blood samples to diagnose brain damage.

Analyzing cardiac troponin and GDF-15 detects presymptomatic heart failure, enabling early intervention before irreversible structural damage occurs.

A lateral flow strip detects acute aortic dissection proteins via antibody binding and visible color changes.

Analyzing activated monocyte metabolic markers identifies mitochondrial dysfunction via blood sampling.

Blood-based beta-synuclein quantification via mass spectrometry diagnoses Alzheimer's disease without invasive cerebrospinal fluid collection.

A content delivery service generates customized digital cognitive behavioral therapy programs through automated user driver assessment.

Combining neurophysin II with BNP markers resolves insufficient early detection of heart failure patients.

Composite biomarker assessment using BNP, Galectin-3, and ST2 levels to stratify heart failure risk and guide targeted therapy intensification.